Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 457-464

  Santarelli, Lory ^a   Staffolani, Sara ^a   Strafella, Elisabetta ^a   Nocchi, Linda ^a   Manzella, Nicola ^a   Grossi, Paola ^a   Bracci, Massimo ^a   Pignotti, Elettra ^b   Alleva, Renata ^b   Borghi, Battista ^b   Pompili, Cecilia ^c   Sabbatini, Armando ^c   Rubini, Corrado ^a   Zuccatosta, Lina ^c   Bichisecchi, Elisabetta ^c   Valentino, Matteo ^a   Horwood, Keith ^d   Comar, Manola ^e   Bovenzi, Massimo ^e   Dong, Lan Feng ^f   Neuzil, Jiri ^f,g   Amati, Monica ^a   Tomasetti, Marco ^a   more..

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c United Hospitals   (Italy)

^d GREENSLOPES PRIVATE HOSPITAL   (Australia)

^e UNIVERSITY OF TRIESTE   (Italy)

^f GRIFFITH UNIVERSITY   (Australia)

^g INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

Author keywords

Early diagnosis; Epigenetic biomarkers; Lung cancer; Mesothelin; Mesothelioma; Methylated gene thrombomodulin; miR 126

Indexed keywords

ASBESTOS; MESOTHELIN; MICRORNA 126; THROMBOMODULIN; ABCC5 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MICRORNA; MIRN126 MICRORNA, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TUMOR MARKER;

AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPIGENETICS; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MARKER GENE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; BLOOD; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY;

AGED; BIOMARKERS, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84949321146     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.09.021     Document Type: Article

References (45)

1. LaDou J., Castleman B., Frank A., Gochfeld M., Greenberg M., Huff J., et al. The case for a global ban on asbestos. Environ. Health Perspect. 2010, 118:897-901.
2. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21:2636-2644.
3. Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
4. Scherpereel A., Grigoriu B., Conti M., Gey T., Grégoire M., Copin M.C., et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2006, 173:1155-1160.
5. Amati M., Tomasetti M., Scartozzi M., Mariotti L., Alleva R., Pignotti E., et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol. Biomarkers Prev. 2008, 17:163-170.
6. Hollevoet K., Reitsma J.B., Creaney J., Grigoriu B.D., Robinson B.W., Scherpereel A., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J. Clin. Oncol. 2012, 30:1541-1549.
7. Santarelli L., Strafella E., Staffolani S., Amati M., Emanuelli M., Sartini D., et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 2011, 6:e18232.
8. Tomasetti M., Staffolani S., Nocchi L., Neuzil J., Strafella E., Manzella N., et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin. Biochem. 2012, 45:575-581.
9. Saito Y., Friedman J.M., Chihara Y., Egger G., Chuang J.C., Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun. 2009, 379:726-731.
10. Zhang Y., Wang X., Xu B., Wang B., Wang Z., Liang Y., et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol. Rep. 2013, 30:1976-1984.
11. Zhang Y., Yang P., Sun T., Li D., Xu X., Rui Y., et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat. Cell Biol. 2013, 15:284-294.
12. Tomasetti M., Nocchi L., Staffolani S., Manzella N., Amati M., Goodwin J., et al. MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. Antioxid. Redox Signal. 2014, 21:2109-2125.
13. Jacobs D.I., Mao Y., Fu A., Kelly W.K., Zhu Y. Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray. BMC Urol. 2013, 13:37.
14. Stefansson O.A., Esteller M. Epigenetic modifications in breast cancer and their role in personalized medicine. Am. J. Pathol. 2013, 183:1052-1063.
15. Tian F., Yip S.P., Kwong D.L., Lin Z., Yang Z., Wu V.W. Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol. 2013, 37:708-713.
16. Ponomaryova A.A., Rykova E.Y., Cherdyntseva N.V., Skvortsova T.E., Dobrodeev A.Y., Zav'yalov A.A., et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 2013, 81:397-403.
17. Chan K.C., Lai P.B., Mok T.S., Chan H.L., Ding C., Yeung S.W., et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin. Chem. 2008, 54:1528-1536.
18. Kobatake T., Yano M., Toyooka S., Tsukuda K., Dote H., Kikuchi T., et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol. Rep. 2004, 12:1087-1092.
19. Christensen B.C., Houseman E.A., Godleski J.J., Marsit C.J., Longacker J.L., Roelofs C.R., et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 2009, 69:227-234.
20. Nelson H.H., Almquist L.M., LaRocca J.L., Plaza S.L., Lambert-Messerlian G.M., Sugarbaker D.J., et al. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. Epigenetics 2011, 6:1029-1034.
21. Nocchi L., Tomasetti M., Amati M., Neuzil J., Santarelli L., Saccucci F. Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose) polymerase-1-mediated epigenetic mechanism. J. Biol. Chem. 2011, 286:19478-19488.
22. Amati M., Tomasetti M., Mariotti L., Tarquini L.M., Valentino M., Santarelli L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat. Res. 2008, 655:52-58.
23. Corradi M., Goldoni M., Alinovi R., Tiseo M., Ampollini L., Bonini S., et al. YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. Anticancer Res. 2013, 33:5517-5524.
24. Cristaudo A., Bonotti A., Simonini S., Vivaldi A., Guglielmi G., Ambrosino N., et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J. Thorac. Oncol. 2011, 6:1587-1593.
25. Blanquart C., Gueugnon F., Nguyen J.M., Roulois D., Cellerin L., Sagan C., et al. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J. Thorac. Oncol. 2012, 7:883-889.
26. Muley T., Dienemann H., Herth F.J., Thomas M., Meister M., Schneider J. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer. J. Thorac. Oncol. 2013, 8:947-951.
27. Fukuoka K., Kuribayashi K., Yamada S., Tamura K., Tabata C., Nakano T. Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. Mol. Clin. Oncol. 2013, 1:942-948.
28. Destro A., Ceresoli G.L., Baryshnikova E., Garassino I., Zucali P.A., De Vincenzo F., et al. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up. Lung Cancer 2008, 59:369-376.
29. Goto Y., Shinjo K., Kondo Y., Shen L., Toyota M., Suzuki H., et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009, 69:9073-9082.
30. Cristaudo A., Foddis R., Bonotti A., Simonini S., Vivaldi A., Guglielmi G., et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup. Environ. Med. 2010, 67:233-236.
31. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
32. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15:272-284.
33. Feng R., Chen X., Yu Y., Su L., Yu B., Li J., et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010, 298:50-63.
34. Zhang J., Du Y.Y., Lin Y.F., Chen Y.T., Yang L., Wang H.J., et al. The cell growth suppressor, mir-126, targets IRS-1. Biochem. Biophys. Res. Commun. 2008, 377:136-140.
35. Zhu N., Zhang D., Xie H., Zhou Z., Chen H., Hu T., et al. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol. Cell. Biochem. 2011, 351:157-164.
36. Li X., Zhang G., Luo F., Ruan J., Huang D., Feng D., et al. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol. Rep. 2012, 28:77-84.
37. Li Z., Li N., Wu M., Li X., Luo Z., Wang X. Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol. Cell. Biochem. 2013, 381:233-242.
38. Huang T.H., Chu T.Y. Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talk confers angiogenesis of cervical cancer. Oncogene 2014, 33:3636-3647.
39. Tavazoie S.F., Alarcón C., Oskarsson T., Padua D., Wang Q., Bos P.D., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
40. Zong Y., Huang J., Sankarasharma D., Morikawa T., Fukayama M., Epstein J.I., et al. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E3395-E3404.
41. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 2006, 1:119-150.
42. Dvorak H.F., Weaver V.M., Tlsty T.D., Bergers G. Tumor microenvironment and progression. J. Surg. Oncol. 2011, 103:468-474.
43. Weiler H., Isermann B.H. Thrombomodulin. J. Thromb. Haemost. 2003, 1:1515-1524.
44. Liu P.L., Tsai J.R., Chiu C.C., Hwang J.J., Chou S.H., Wang C.K., et al. Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in non-small cell lung cancer. Mol. Carcinog. 2010, 49:874-881.
45. Cristaudo A., Foddis R., Bonotti A., Simonini S., Vivaldi A., Guglielmi G., et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup. Environ. Med. 2010, 67:233-236.